FAT1:CD3 BsAb and CD19:CD3 (Blinatumomab) BsAb design and production - Evaluating new immunotherapies targeting the FAT1 cadherin in high risk leukaemia (externally led by CCI) (2026-2029)

Dr Christopher Howard

Advance Qld Industry Res Fellow

Australian Institute for Bioengineering and Nanotechnology